RecruitingPhase 2NCT05502315

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Sponsor

Rana McKay, MD

Enrollment

47 participants

Start Date

Feb 2, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Cancer Castration-resistant Prostate Cancer

Summary

This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing the combination of two cancer drugs — cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) — in men with metastatic castration-resistant prostate cancer (mCRPC), meaning prostate cancer that has spread and is no longer responding to hormone therapy. **You may be eligible if...** - You are a male 18 or older with prostate cancer confirmed by biopsy - Your cancer has spread (metastatic) and is progressing despite very low testosterone levels - Your overall health is acceptable (ECOG status 0–2) **You may NOT be eligible if...** - You have pure small cell (neuroendocrine) prostate cancer - You have uncontrolled heart disease or other serious medical conditions - Your organ function does not meet study requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.